Recombinant Anti-CD3 x Anti-PD1 Bispecific Antibody (Bi-sdAb) is designed to be expressed as a VHH from anti-CD3 antibody variable domains fused with a VHH from an anti-PD1 antibody variable domains. It contains a His-tag at the C/N terminus for affinity purification. The BsAb exits as monomer in reducing and non-reducing conditions. This BsAb can retarget T cells to tumor cells. It is designed for the research of Esophageal cancer; Hodgkin lymphoma; Renal cell cancer (RCC); Mesothelioma; Head and neck squamous cell cancer (HNSCC); Anal cancer; Gastric cancer; Hepatocellular cancer; Nasopharyngeal cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.
There are currently no customer reviews or questions for Recombinant Anti-CD3 VHH x Anti-PD1 VHH BispecificAntibody (Bi-sdAb) (BIVHH-031). Click the button below to contact us or submit your feedback about this product.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRYSERVICES
PRODUCTS
PLATFORMS